Invesco Ltd. Aquestive Therapeutics, Inc. Transaction History

Invesco Ltd.

$600 Billion
Q3 2025

A detailed history of Invesco Ltd. transactions in Aquestive Therapeutics, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 54,073 shares of AQST stock, worth $291,453. This represents 0.0% of its overall portfolio holdings.

Number of Shares

54,073

Previous 52,813 2.39%

Holding current value

$291,453

Previous $174,000 73.56%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	BUY	$3.4 - $5.99 $4,284 - $7,547	1,260 Added 2.39%	54,073 $302,000
Q2 2025 Aug 13, 2025	SELL	$2.22 - $3.58 $628 - $1,013	-283 Reduced 0.53%	52,813 $174,000
Q1 2025 May 12, 2025	BUY	$2.54 - $3.75 $13,086 - $19,320	5,152 Added 10.75%	53,096 $153,000
Q4 2024 Feb 13, 2025	SELL	$3.46 - $5.64 $2.56 Million - $4.17 Million	-738,635 Reduced 93.9%	47,944 $169,000
Q3 2024 Nov 12, 2024	BUY	$2.4 - $5.09 $1.67 Million - $3.55 Million	697,538 Added 783.39%	786,579 $3.92 Million

Q2 2024 Aug 13, 2024	SELL	$2.31 - $4.5 $1.87 Million - $3.64 Million	-808,471 Reduced 90.08%	89,041 $231,000
Q1 2024 May 14, 2024	BUY	$2.01 - $6.09 $1.8 Million - $5.47 Million	897,512 New	897,512 $3.82 Million
Q2 2021 Aug 17, 2021	SELL	$3.29 - $5.21 $38,022 - $60,211	-11,557 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$4.17 - $6.73 $881,700 - $1.42 Million	-211,439 Reduced 94.82%	11,557 $60,000
Q4 2020 Feb 16, 2021	SELL	$4.65 - $7.79 $1.88 Million - $3.15 Million	-404,448 Reduced 64.46%	222,996 $1.19 Million
Q3 2020 Nov 16, 2020	BUY	$4.12 - $9.09 $2.59 Million - $5.7 Million	627,444 New	627,444 $3.05 Million

Others Institutions Holding AQST

# of Institutions

163

Shares Held

65.9M

Call Options Held

794K

Put Options Held

457K

View Full List

About Aquestive Therapeutics, Inc.

Ticker AQST
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,350,700
Market Cap $288M
Description
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual f...

More about AQST

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account